What Angel said in May regarding Sal and his 26b...
Read very closely, reflects statement in fins on "Control Shares."
New E-mail from Angel - 5/23/2014, 7:03PM
This is what was asked in a follow up to Angel, Can you share your timeline thereafter for submitting the name/ticker change?
RE: Mr. Tuzzolino and the capital investment. We expected to see a line-item entry indicating the revenue received. $2.7M was suggested to me, based on the share conversion rate of 27 billion to .0001. That was not clear in the balance sheet...
Angel Stanz (BG Medical) To Me Today at 7:03 PM BN,
I will be able to set timeline expectations more appropriately after I know that OTC has everything they need.
Your comments are not quite the correct thought path in regards to Tuzzolino. I will explain more in detail as relevant, but some information will unfold as future milestones are reached. Sal is integral to the engine. The turn around strategy that you are seeing occur is the result of significant planning laid down with Sal, myself, and others through generous portions of 2013. His interests are not short term, but rather are as long as my own. His background is M&A. His pedigree is Purdue and Duke, with the commensurate professional network that compliments this background and experience. This is all relevant to going forward plans.
Recall if you will the primary reasons behind the modified share structure. Sal is serving within the interests of the organization and shareholders, while furthering the strategies to limit outside harm. He is an ally.
I cannot tell you the end of chapter 20 while we are only finishing chapter 2. One, it would not make sense. Two, it would also spoil the ride. Business is dynamic and I will not be held to a publicly-stated strategy that will surely shift as the industry shifts with it. Apple is not going to reveal to shareholders what product they will produce in 2019, but I assure you, they are already working on it today. If they revealed this, competitors would eat them alive and destroy shareholder value. BG Medical is a public company, not an open-source company. In a general sense, protecting strategic information is good for company value and good for personal gains of shareholders. The Apple analogy applies to any well run company, public or otherwise. Granted, disclosures are important and these will absolutely continue as well as increase in frequency (as appropriate).
To this end, as time progresses I will key up more on strategy, opportunities, and industry markers. I will talk less on products to come, and more on products released. We will highlight more accomplishments, and discuss fewer promises. This is a shift away from "pink sheet conjecture" with a greater focus on "big board behavior". For who we are as a company, we had the wrong advisors clinging on in 2012, the remnants of a sordid RIGH past that I was not involved in. That era is over. The BGMT, BMED, or BUDG era is now set to begin. Of course we will engage in conversations about development, market share, and opportunity. We are still a young company with much growth ahead. Highlighting all of this is important to shareholders. Our DNA, who we are, and how we function, are key factors that differentiate our opportunity from others in the medical marijuana space. This dialogue will continue -- with you, with other shareholders, and publicly.
What can be seen today is progress. What can also be seen is new transparency. Publicly, we have now explained the dark period and why. The numbers mirror the story across all fronts (revenue, equity, structure). We have also announced the end of the dark period. I am communicating. The company is communicating. Our social media is communicating. The company status will be changed next week by OTC. Actions are ramping up.
.................... I held my tongue for many months so that we could tell the true story in the proper venue with proper strategies in play. I had no intent of engaging prematurely. I am patient. As a company, we are methodical. The squak-box-of-the-week has no affect on our future. Progress will tell our story and I feel no obligation to rush the ending (but if this gets any more preposterous, I'm going to buy a mal-tempered jack russell terrier for the office with a tin foil hat and name it "************" for posterity).
Much has been done, and there is more to come.
Enjoy your Memorial Day weekend. We are all looking forward to OTC Current early next week.
Warm Regards, Angel Stanz, CEO BG Medical Technologies, Inc. RightSmile, Inc. ************@bgmedtech.com (855) 723-3283”
